Skip to main content
Clinical Trials/NCT04497272
NCT04497272CompletedNot Applicable

Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)

Centre Hospitalier Universitaire de Nice1 site in 1 country150 target enrollmentStarted: August 7, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
150
Locations
1
Primary Endpoint
Identifying the metabolomic signature

Study Overview

Brief Summary

Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or biological fluids). It can potentially detect very sensitively any change related to a pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore applicable in routine, particularly in health care. Given the emergence of this new disease, COVID-19, there is a real need to better understand the pathophysiological mechanisms of SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the development of interesting diagnostic or prognostic tools. The objective of this study is to identify, through the analysis of biological samples (blood and urine), whether there is a metabolomic signature in patients with COVID-19.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •patient over 18 years of age
  • •affiliated to a social security scheme
  • •consultant in the emergency department and/or being hospitalized for suspected SARS CoV infection
  • •confirmation, after medical examination, of the need for a biological examination (this will negate the need for additional venipuncture)

Exclusion Criteria

  • •Patient who do not meet inclusion criteria
  • •Person subject to a guardianship order
  • •Opposition to the use of the data or samples (withdrawal of non-opposition) / Sponsor's or investigator's decision

Arms & Interventions

The metabolomic signature of COVID-19 patients

Other

It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.

Intervention: COVID-19 patients (Other)

Outcomes

Primary Outcomes

Identifying the metabolomic signature

Time Frame: Enrollment

To dentified a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients

Secondary Outcomes

  • Identification of the metabolomic profile according to clinical severity.(Enrollment)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials